Mycophenolate mofetil in pediatric renal transplantation

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 91-99

  Weber, L T ^a   Hocker B ^a   Mehls, O ^a   Tonshoff B ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Child; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

BIOAVAILABILITY; BLOOD PRESSURE REGULATION; BONE MARROW TOXICITY; CYTOPENIA; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFECTION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; NEUROTOXICITY; RECIPIENT; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

ADRENAL CORTEX HORMONES; ADULT; CHILD; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0038787739     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Benfield MR, Stablein D, Tejani A. Trends in immunosupressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999;3:27-32.
2. Lee Wa, Gu L, Mikstal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990;7:161-6.
3. Sweeney MJ. Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot 1977;30 Suppl:85-92.
4. Allison AC, Eugui EM. The design and the development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993;14: 353-80.
5. Allison AC, Hovi T, Watts RWE, Webster ADB. Immunological observations on patients with Lesch-Nyhan syndrome, and the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975;2:1179-82.
6. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993;685: 309-29.
7. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10:77-84.
8. Natsudema Y, Carr SF. Human type I and II IMP dehydrogenase as drug targets. Ann N Y Acad Sci 1993;696: 88-93.
9. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113: 515-24.
10. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolate acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994;26:3205-10.
11. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996;61:722-9.
12. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995;345: 1321-5.
13. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
14. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47:215-45.
15. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9.
16. Mathew TH for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomised multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998;65:1450-4.
17. Sarmiento JM, Munn SR, Paya CV, Velosa JA, Nyuyen JH. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study. Clin Transplant 1998;12:371-4.
18. Ettenger R, Cohen A, Nast C, Moulton L, Marik J, Gales B. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997;28:340-1.
19. Benfield MR, Symons JM, Bynon S, Eckhoff D, Herrin J, Harmon W et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999;3:33-7.
20. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998;9:1511-20.
21. Staskewitz A, Kirste G, Tönshoff B, Weber LT, Böswald M, Burghard R et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. Transplantation 2001;71:638-44.
22. Jungraithmayr T, Staskewitz A, Kirste G, Böswald M, Bulla M, Burghard R et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003;75:454-61.
23. Bunchman T, Navarro M, Broyer M, Sherbotie J, Chavers B, Tönshoff B et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001;16:978-84.
24. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
25. Ducloux D, Motte G, Billerey C, Bresson-Vautrin C, Vautrin P, Rebibou JM et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int 2002;15:387-92.
26. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P et al. Cyclosporine withdrawal from mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomised, controlled study. Transplantation 2002;74:1725-34.
27. David-Neto E, Araujo LM, Lemos FC, David DS, Mazzucchi E, Nahas WC et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001;5:302-9.
28. Grinyo JM, Gil-Vernet S, Serón D, Cruzado JM, Moreso F, Fulladosa X et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997;63:1688-90.
29. Puig i Mari JM on behalf of the Spanish Group of the CellCept Study. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Transplant Proc 1999;31:2256-8.
30. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W et al. Withdrawal of cyclosporine or prednisone 6 months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365-73.
31. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on Cyclosporine and Mycophenolate Mofetil. A prospective randomised study. Transplantation 1999;68:1865-74.
32. Birkeland SA. Steroid-free Immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998;66: 1207-10.
33. Höcker B, Plank C, John U, Wühl E, Weber LT, Rascher W et al. Withdrawal of steroids in stable pediatric renal transplant recipients on cyclosporin A and MMF. A case control study. Pediatr Nephrol 2002;17:C137.
34. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13-21.
35. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002;62:1060-7.
36. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB et al. Area under the concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit 1999;21:498-506.
37. Shaw LM, Mick R, Nowack I, Korecka M. Pharmacokinetics of mycophenolic acid in renal transplant recipients with delayed graft function. J Clin Pharmacol 1998;38:268-75.
38. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999;39:715-20.
39. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759-68.
40. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998;31:317-22.
41. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64: 672-83.
42. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68:1603-6.
43. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
44. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002;48:517-25.
45. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiss G et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999;126:1075-82.
46. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000;46:365-72.
47. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999;45:419-22.
48. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, Oellerich M et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001;33:1080-1.
49. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002;24:390-9.
50. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP et al. A randomised doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-6.
51. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998;65: 1127-9.
52. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS 61443). A short review. Transplant Proc 1996;28:925-9.
53. Nowak J, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-7.
54. Briggs WA, Choi MJ, Scheel PJ. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31:213-7.
55. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001;15:402-9.
56. Sullivan S, Garrison L, Best J. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. J Am Soc Nephrol 1997;8:1592-8.